Greenwich Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.13M | Sell |
8,881
-480
| -5% | -$59.9K | 0.05% | 145 |
|
|
2025
Q4 | $1.14M | Sell |
9,361
-55
| -0.6% | -$6.31K | 0.05% | 145 |
|
|
2025
Q3 | $943K | Buy |
9,416
+10
| +0.1% | +$901 | 0.05% | 150 |
|
|
2025
Q2 | $780K | Sell |
9,406
-1,031
| -10% | -$82.3K | 0.04% | 145 |
|
|
2025
Q1 | $846K | Sell |
10,437
-536
| -5% | -$47.9K | 0.06% | 126 |
|
|
2024
Q4 | $988K | Sell |
10,973
-284
| -3% | -$27.5K | 0.07% | 119 |
|
|
2024
Q3 | $1.11M | Sell |
11,257
-248
| -2% | -$24.4K | 0.08% | 113 |
|
|
2024
Q2 | $1.07M | Buy |
11,505
+1,073
| +10% | +$96.2K | 0.08% | 109 |
|
|
2024
Q1 | $990K | Sell |
10,432
-1,019
| -9% | -$94.6K | 0.08% | 113 |
|
|
2023
Q4 | $1.02M | Buy |
11,451
+155
| +1% | +$11.5K | 0.1% | 102 |
|
|
2023
Q3 | $825K | Sell |
11,296
-207
| -2% | -$16.5K | 0.09% | 112 |
|
|
2023
Q2 | $957K | Buy |
11,503
+445
| +4% | +$37.2K | 0.1% | 106 |
|
|
2023
Q1 | $843K | Buy |
11,058
+882
| +9% | +$73.2K | 0.09% | 116 |
|
|
2022
Q4 | $845K | Sell |
10,176
-80
| -0.8% | -$6.48K | 0.09% | 117 |
|
|
2022
Q3 | $814K | Buy |
10,256
+262
| +3% | +$22.1K | 0.09% | 120 |
|
|
2022
Q2 | $742K | Buy |
9,994
+984
| +11% | +$73.9K | 0.1% | 128 |
|
|
2022
Q1 | $810K | Buy |
9,010
+1,661
| +23% | +$153K | 0.08% | 124 |
|
|
2021
Q4 | $823K | Buy |
7,349
+1,049
| +17% | +$127K | 0.07% | 126 |
|
|
2021
Q3 | $792K | Sell |
6,300
-58
| -0.9% | -$7.47K | 0.07% | 123 |
|
|
2021
Q2 | $861K | Sell |
6,358
-649
| -9% | -$85.3K | 0.07% | 119 |
|
|
2021
Q1 | $951K | Buy |
7,007
+58
| +0.8% | +$8.68K | 0.08% | 104 |
|
|
2020
Q4 | $978K | Sell |
6,949
-840
| -11% | -$108K | 0.09% | 93 |
|
|
2020
Q3 | $868K | Buy |
7,789
+210
| +3% | +$23.5K | 0.16% | 91 |
|
|
2020
Q2 | $848K | Sell |
7,579
-3,854
| -34% | -$380K | 0.16% | 90 |
|
|
2020
Q1 | $885K | Sell |
11,433
-192
| -2% | -$17K | 0.19% | 79 |
|
|
2019
Q4 | $1.11M | Sell |
11,625
-254
| -2% | -$22K | 0.22% | 79 |
|
|
2019
Q3 | $906K | Sell |
11,879
-626
| -5% | -$52K | 0.18% | 92 |
|
|
2019
Q2 | $1.1M | Buy |
12,505
+1,308
| +12% | +$112K | 0.19% | 83 |
|
|
2019
Q1 | $1.01M | Sell |
11,197
-177
| -2% | -$15.1K | 0.18% | 83 |
|
|
2018
Q4 | $816K | Buy |
11,374
+264
| +2% | +$21.3K | 0.16% | 88 |
|
|
2018
Q3 | $1.06M | Buy |
11,110
+302
| +3% | +$29.3K | 0.19% | 81 |
|
|
2018
Q2 | $1.03M | Sell |
10,808
-63
| -0.6% | -$5.79K | 0.18% | 79 |
|
|
2018
Q1 | $954K | Buy |
10,871
+224
| +2% | +$20.4K | 0.15% | 80 |
|
|
2017
Q4 | $904K | Sell |
10,647
-85
| -0.8% | -$7.12K | 0.15% | 86 |
|
|
2017
Q3 | $929K | Buy |
10,732
+209
| +2% | +$16.8K | 0.16% | 81 |
|
|
2017
Q2 | $812K | Buy |
10,523
+3,313
| +46% | +$235K | 0.14% | 88 |
|
|
2017
Q1 | $500K | Buy |
7,210
+1,941
| +37% | +$130K | 0.07% | 110 |
|
|
2016
Q4 | $312K | Sell |
5,269
-424
| -7% | -$26.2K | 0.04% | 154 |
|
|
2016
Q3 | $377K | Buy |
5,693
+400
| +8% | +$24.7K | 0.07% | 142 |
|
|
2016
Q2 | $286K | Sell |
5,293
-27
| -0.5% | -$1.48K | 0.07% | 153 |
|
|
2016
Q1 | $275K | Buy |
+5,320
| New | +$276K | 0.07% | 153 |
|
Other funds holding XBI
Greenwich Wealth Management's XBI Position: Q1 2026 in Review
Greenwich Wealth Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5.1% in Q1 2026, selling an estimated $59.9K and leaving 8,881 shares worth $1.13M. The position accounts for 0.05% of the portfolio, ranked #145.
Greenwich Wealth Management first reported a position in XBI in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.14M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Greenwich Wealth Management held 8,881 shares of State Street SPDR S&P Biotech ETF worth $1.13M as of Q1 2026.
- Greenwich Wealth Management sold 480 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $59.9K.
- State Street SPDR S&P Biotech ETF made up 0.05% of Greenwich Wealth Management's portfolio in Q1 2026, its #145 holding.
- Greenwich Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 41 quarters since.
- Greenwich Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $1.14M in Q4 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Greenwich Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.